Results 181 to 190 of about 55,803 (311)

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

Immunoglobulins are beneficial in SARS-CoV-2 vaccine-induced small fibre neuropathy even 3 years after onset. [PDF]

J Family Med Prim Care
Finsterer J.
europepmc   +1 more source

Clinical Images: Sevoflurane‐induced periostitis

Arthritis &Rheumatology, EarlyView.
Christian Beyer, Marion Ganslmayer, Richard Strauß, Bernhard Manger   +3 more
wiley   +1 more source

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, EarlyView.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

Subacute sclerosing panencephalitis in a child six years after measles infection. [PDF]

IDCases
Le Feur L, Henry S, Jeziorski E, Dina J, Piarroux J, Meyer P, Foulongne V.   +6 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG? [PDF]

Front Immunol
Camacho-Ordonez N, Hirsch A, Campos L, Goldacker S, Burns SO, Moreira F, Warnatz K, Grimbacher B.   +7 more
europepmc   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

A Pediatric Case of Stiff-Person Syndrome: Presentation and Comparative Analysis. [PDF]

J Orthop Case Rep
Alaeddine L, Sami B, Ismail K, Seifeddine T, Zied J, Mahmoud S.   +5 more
europepmc   +1 more source

Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing. [PDF]

Support Care Cancer
de Albornoz SC, Haysom H, Mo A, Guglielmino J, Dunstan T, Rushford K, Ellison A, Saxby K, Andrew D, Jesurajah A, Banahene P, Hu E, Hoo LS, Petrie D, Wood EM, Higgins AM, McQuilten ZK.   +16 more
europepmc   +1 more source